|
May 7
|
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
|
|
May 7
|
Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase
|
|
May 7
|
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
|
|
May 7
|
Esperion Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
Esperion to Participate in Upcoming May Investor Conferences
|
|
Apr 25
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Apr 23
|
Esperion to Report First Quarter 2024 Financial Results on May 7
|
|
Apr 21
|
11 Best Low Price Pharma Stocks To Invest In
|
|
Apr 7
|
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
|
|
Apr 1
|
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
|
|
Mar 28
|
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
|
|
Mar 26
|
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 25
|
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
|
|
Mar 22
|
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
|
|
Mar 22
|
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
|
|
Mar 22
|
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
|
|
Mar 5
|
11 Best Small Cap Pharma Stocks to Invest In
|
|
Feb 1
|
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
|
|
Jan 3
|
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
|
|
Dec 18
|
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
|